 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...1718192021222324252627...858859» |
- Real-world observational study of patients with endocrine-resistant, hormone receptor+, HER2- metastatic breast cancer in the first-line setting: Patient characteristics, PIK3CA mutation prevalence, treatments, and clinical outcomes (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1678;
- CDK 4/6 inhibitor switching and associated dosing patterns in Swedish HR+/HER2- MBC patients (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1677;
- Verzenio (abemaciclib) / Eli Lilly
Prospective Cohort Study of Abemaciclib in Combination with Endocrine Therapy for Chemotherapy-Treated HR+/HER2- Metastatic Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1675;
- Kisqali (ribociclib) / Novartis, Itovebi (inavolisib) / Roche, Verzenio (abemaciclib) / Eli Lilly
Preliminary safety in the inavolisib + fulvestrant + ribociclib/abemaciclib arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy & safety of multiple treatment combinations in patients with metastatic/locally advanced breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1674;
- Ibrance (palbociclib) / Pfizer
Real world effectiveness of overall survival (OS) with palbociclib (PAL) plus (+) endocrine therapy (ET) in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) patients in Japan (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1673;
- Is Distance to Treating Oncologist a Potential Prognostic Real-World-Factor for Patients with HR+/HER2- Advanced Breast Cancer? Results from the Non-Interventional Study PERFORM (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1671;
- Ibrance (palbociclib) / Pfizer
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1670;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1604;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Excellent and Prolonged Response to Sacituzumab-govitecan in Triple Negative mBC (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1599;
- MINDY1 role and exceptional response to CDK inhibitors in metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1562;
- Comparative budget impact of CDK 4/6 inhibitors at a Mexican public healthcare institution (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1514;
- Transparency for patient assistance and compassionate use programs for high-cost intravenous and oral therapies in breast cancer patients at an NCI-designated cancer center (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1509;
- Contemporary patterns of Medicare Utilization and Spending on Herceptin and its Biosimilars in Breast Cancer. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1473;
- Medication Nonadherence and Financial Toxicity Among Patients with Metastatic Breast Cancer on Cyclin Dependent Kinase 4/6 Inhibitors. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1471;
- Ibrance (palbociclib) / Pfizer
Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma. (Stars at Night 3-4) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1462;
- Real-World Efficacy and Outcomes of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer: A Retrospective Analysis from Russia (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1402;
- Cyclin inhibitors for breast cancer: A comparative real world data analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1276;
- Current Treatment Strategies for PIK3CA-Mutated Metastatic Breast Cancer and Provider Perceptions of the INAVO120 Trial (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1266;
- Efficacy of first-line CDK4/6 inhibitors stratified by ER, PR, HER2 expression levels and Ki-67 in hormone receptor-positive, HER2 negative metastatic breast cancer: Real-world outcomes (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1210;
- Ibrance (palbociclib) / Pfizer
Dynamic increases in T cell repertoire diversity determine palbociclib efficacy and improved antitumor immune response (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1209;
- Extreme ESR1 polyclonality, mutational dynamics and effects on treatment outcomes in patients with ER+ metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1200;
- The impact of ethnicity on benefit from novel drugs approved for breast cancer treatment: a systematic review and meta-analysis of randomized phase 3 trials of the last decade. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1186;
- Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1184;
- Inhibition of FASN and ACC1 as a Potential Treatment for Advanced Endocrine Therapy-Resistant Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1183;
- An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1175;
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Evaluation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal novel therapeutic opportunities in ER+/HER2- breast cancers (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1120;
- CDK4/6 inhibitor resistance in patients with ER+ breast cancer: Identification and characterization of resistance mechanisms in thirty-two XPDX models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1117;
- Simultaneous loss of BRCA2 and RB1 results in growth disadvantage but strong CDK4/6i resistance in HR+/HER2- breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1116;
- Prolia (denosumab) / Amgen
Phase II, Single Arm Trial of Denosumab's Effect on Breast Density and Breast Tissue Biomarkers (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1102;
- vepdegestrant (ARV-471) / Arvinas, Pfizer, Ibrance (palbociclib) / Pfizer
Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, Plus Palbociclib in CDK4/6 Inhibitor-Resistant WT ER and ER Y537S Mutant Patient-Derived Xenograft (PDX) Models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1084;
- Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC). (Stars at Night 3-4) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1035;
- Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_995;
- Association of MammaPrint (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_994;
- Comparative overall survival of CDK4/6is plus an aromatase inhibitor (AI) in HR+/HER2- MBC in the US real-world setting. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_989;
- A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_972;
- Clinical, genetic and immunological features, HER2-low expression and treatment patterns in a large population of male breast cancer patient with long-term follow up (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_964;
- camizestrant (AZD9833) / AstraZeneca, saruparib (AZD5305) / AstraZeneca
A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician's choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_912;
- Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_896;
- Real-world comparative efficacy of CDK4/6 inhibitors in first-line treatment of HR+/HER2- metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_895;
- Piqray (alpelisib) / Novartis
Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_892;
- Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_891;
- Differential outcomes of patients with HR-positive/HER2-negative metastatic breast cancer and a pathogenic BRCA1/2 or PALB2 variant under first line CDK4/6 inhibition (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_888;
- Ibrance (palbociclib) / Pfizer, Itovebi (inavolisib) / Roche
First-line inavolisib/placebo + palbociclib + fulvestrant in PIK3CA-mutated, hormone receptor+, HER2- locally advanced/metastatic breast cancer w/ relapse during/within 12 months of adjuvant endocrine therapy completion: INAVO120 long-term safety (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_887;
- Efficacy of cyclin-dependent kinase 4/6 inhibitor + endocrine therapy in patients w/ hormone receptor-positive, HER2-negative advanced or metastatic breast cancer w/ liver or lung only metastases: a US Food & Drug Administration pooled analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_884;
- palazestrant (OP-1250) / Olema Pharma, Kisqali (ribociclib) / Novartis
A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_881;
- Implementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older Breast Cancer patients (IMPORTANT trial) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_864;
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Comparative effects of Ribociclib, Palbociclib, and Abemaciclib on circulating and tumor infiltrating myeloid cells in metastatic breast cancer patients (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_853;
- Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_845;
- Ibrance (palbociclib) / Pfizer
DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_836;
- onvansertib (PCM-075) / Cardiff Oncology
Onvansertib shows synergistic efficacy in combination with paclitaxel in HR+ breast cancer: Mechanistic insights from preclinical models (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_832;